INCY

Incyte Corp

Add to Watchlist

Advanced Chart

78.390

+0.19(0.243%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

79.000

Open

78.240

VWAP

78.39

Vol

1.20M

Mkt Cap

15.31B

Low

77.6901

Amount

94.09M

EV/EBITDA(TTM)

11.87

Total Shares

197.01M

12.89B

EV/OCF(TTM)

12.85

P/S(TTM)

3.41

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

1.18B

+12.38%

1.347

+16.11%

1.32B

+11.58%

1.804

+26.16%

1.25B

+10.22%

1.671

+56.15%

Estimates Revision

The market is revising Upward the revenue expectations for Incyte Corporation (INCY) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by 32.91%.

Revenue Estimates for FY2025

Revise Upward

+0.21%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.14%

In Past 3 Month

Stock Price

Go Up

+32.91%

In Past 3 Month

17 Analyst Rating

1.54% Upside

Wall Street analysts forecast INCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCY is 79.60 USD with a low forecast of 52.00 USD and a high forecast of 107.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

9 Hold

1 Sell

Moderate Buy

1.54% Upside

Current: 78.390

Low

52.00

Averages

79.60

High

107.00

1.54% Upside

Current: 78.390

Low

52.00

Averages

79.60

High

107.00

Wells Fargo

Equal Weight

Overweight

upgrade

$67 -> $89

2025-08-06

New

Reason

Wells Fargo

Price Target

$67 -> $89

2025-08-06

New

upgrade

Equal Weight

Overweight

Reason

Wells Fargo upgraded Incyte to Overweight from Equal Weight with a price target of $89, up from $67. The firm believes the company's Phase 1 update for myelofibrosis in Q4 will be positive. In addition, the potential for research and development "rationalization" along with future business development provides upside for the stock, the analyst tells investors in a research note. Wells believes Incyte can address its Jakafi loss of exclusivity.

Barclays

Overweight

initiated

$90

2025-08-01

Reason

Barclays

Price Target

$90

2025-08-01

initiated

Overweight

Reason

Barclays initiated coverage of Incyte with an Overweight rating and $90 price target. The firm sees \"value-inflecting\" data readouts for the company in the second half of 2025 and 2026. It believes the pivotal data for tafasitamab in diffuse large B-cell lymphoma and the Phase 2 data for povorcitinib in chronic spontaneous urticaria patients as providing the next legs of growth for Incyte.

Citi

Buy

maintain

$88 -> $103

2025-07-30

Reason

Citi

Price Target

$88 -> $103

2025-07-30

maintain

Buy

Reason

Citi raised the firm's price target on Incyte to $103 from $88 and keeps a Buy rating on the shares post the Q2 report. The company reported another beat and guidance raise for Jakafi with upside for Niktimvo, the analyst tells investors in a research note.

UBS

Neutral

maintain

$62 -> $68

2025-07-30

Reason

UBS

Price Target

$62 -> $68

2025-07-30

maintain

Neutral

Reason

UBS raised the firm's price target on Incyte to $68 from $62 and keeps a Neutral rating on the shares.

BMO Capital

Evan Seigerman

Underperform

maintain

$52 -> $60

2025-07-30

Reason

BMO Capital

Evan Seigerman

Price Target

$52 -> $60

2025-07-30

maintain

Underperform

Reason

BMO Capital analyst Evan Seigerman raised the firm's price target on Incyte to $60 from $52 but keeps an Underperform rating on the shares after its Q2 earnings beat. While the firm is encouraged by earnings, there is work to be done, the analyst tells investors in a research note. BMO adds that it "appreciates the perspective of impartiality" when assessing internal and external growth opportunities, but Incyte's modest cash positioning could be growth-limiting for transactions.

Truist

Srikripa Devarakonda

Hold

maintain

$73 -> $79

2025-07-30

Reason

Truist

Srikripa Devarakonda

Price Target

$73 -> $79

2025-07-30

maintain

Hold

Reason

Truist analyst Srikripa Devarakonda raised the firm's price target on Incyte to $79 from $73 and keeps a Hold rating on the shares after its Q2 earnings and revenue beat. Increased demand from Jakafi exceeded expectations, but the looming Jakafi loss of exclusivity remains a key overhang, and the firm remains on the sidelines for now, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Incyte Corp (INCY.O) is 11.94, compared to its 5-year average forward P/E of 20.37. For a more detailed relative valuation and DCF analysis to assess Incyte Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

20.37

Current PE

11.94

Overvalued PE

28.18

Undervalued PE

12.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

16.93

Current EV/EBITDA

7.97

Overvalued EV/EBITDA

26.37

Undervalued EV/EBITDA

7.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.38

Current PS

3.01

Overvalued PS

5.77

Undervalued PS

2.99

Financials

Annual

Quarterly

FY2025Q2

YoY :

+16.46%

1.22B

Total Revenue

FY2025Q2

YoY :

-169.73%

310.82M

Operating Profit

FY2025Q2

YoY :

-191.09%

405.00M

Net Income after Tax

FY2025Q2

YoY :

-200.00%

2.04

EPS - Diluted

FY2025Q2

YoY :

-104.07%

25.67M

Free Cash Flow

FY2025Q2

YoY :

+0.93%

93.52

Gross Profit Margin - %

FY2025Q2

YoY :

-669.61%

20.62

FCF Margin - %

FY2025Q2

YoY :

-178.22%

33.32

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.5M

USD

3-6

Months

1.4M

USD

6-9

Months

2.0M

USD

0-12

Months

1.3M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

166.5K

Volume

6-9

Months

546.9K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

294.2K

Volume

Months

6-9

596.2K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

16.0K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.5M

USD

3-6

Months

1.4M

USD

6-9

Months

2.0M

USD

0-12

Months

1.3M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

INCY News & Events

Events Timeline

2025-08-06 (ET)

2025-08-06

08:47:54

Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial

2025-07-29 (ET)

2025-07-29

07:26:13

Incyte raises FY25 Jakafi revenue view to $3B-$3.05B from $2.95B-$3B

2025-07-29

07:24:53

Incyte reports Q2 EPS $1.57, consensus $1.48

News

7.5

08-04Globenewswire

Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

6.0

08-01Benzinga

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

9.0

07-31Newsfilter

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

People Also Watch

Anglogold Ashanti PLC

Performance Food Group Co

Akamai Technologies Inc

FAQ

What is Incyte Corp (INCY) stock price today?

The current price of INCY is 78.39 USD — it has increased 0.24 % in the last trading day.

INCY

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

INCY News & Events

Events Timeline

News

People Also Watch

FAQ

What is Incyte Corp (INCY) stock price today?

What is Incyte Corp (INCY)'s business?

What is the price predicton of INCY Stock?

What is Incyte Corp (INCY)'s revenue for the last quarter?

What is Incyte Corp (INCY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Incyte Corp (INCY)'s fundamentals?

How many employees does Incyte Corp (INCY). have?

What is Incyte Corp (INCY) market cap?